Brought to you by 
On the heels of FDA approval, Anacor partners Kerydin with Sandoz’s PharmaDerm
01 Jul 2015
Executive Summary
Less than two weeks after gaining FDA approval for its antifungal drug Kerydin (tavaborole), Anacor Pharmaceuticals Inc. (boron-based small molecules) licensed PharmaDerm (a division of Sandoz Inc.’s now-absorbed Fougera division) exclusive US rights to market and sell the product. Sandoz also received a right of first negotiation to develop and commercialize in the US other tavaborole formulations and Anacor’s Phase I/Kerydin back-up compound AN2718 for nonsystemic fungal infections including Trichophyton and Candida fungi.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Topical Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
On the heels of FDA approval, Anacor partners Kerydin with Sandoz’s PharmaDerm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice